Table 4.
CANCER | Antigen | STRATEGY | NCT NUMBER | PHASE |
---|---|---|---|---|
Acute Myeloid Leukemia | WT-1 | RNA-pulsed DC | NCT01686334 | Phase 2 |
WT-1 | RNA-pulsed DC | NCT00834002 | Phase 1 | |
Breast | Multiple antigens | DNA vaccine | NCT02157051 | Phase 1 |
CEA | RNA-pulsed DC | NCT00003432 | Phase 1/2 | |
Colorectal | CEA | RNA-pulsed DC | NCT00003433 | Phase 1/2 |
Kidney | hPSMA | DNA | NCT00096629 | Phase 1 |
Lymphoma | Idiotype | DNA | NCT01209871 | Phase 1 |
Melanoma | Multiple | RNA | NCT00204516 | Phase 1/2 |
tyrosinase-related peptide 2 (TRP2) | RNA-pulsed DC | NCT01456104 | Phase 1 | |
Neo-antigens | RNA | NCT01684241 | Phase 1 | |
Neo-antigens | RNA | NCT02035956 | Phase 1 | |
gp100 and tyrosinase | RNA-pulsed DC | NCT00940004 | Phase 1/2 | |
gp100 and tyrosinase | RNA-pulsed DC | NCT00243529 | Phase 1/2 | |
Multiple | RNA-pulsed DC | NCT01216436 | Phase 1 | |
gp100 and tyrosinase | RNA-pulsed DC | NCT01530698 | Phase 1/2 | |
Multiple | RNA-pulsed DC | NCT00672542 | Phase 1 | |
Multiple | CEA | RNA-pulsed DC | NCT00004604 | Phase 1 |
NY-ESO-1 | DNA | NCT00199849 | Phase 1 | |
Non Small Cell Lung | Multiple | RNA | NCT00923312 | Phase 1/2 |
Multiple | RNA | NCT01915524 | Phase 1 | |
Prostate | Multiple | RNA | NCT00906243 | Phase 1/2 |
PSA | DNA | NCT00859729 | Phase 1/2 | |
PSA | RNA-pulsed DC | NCT00004211 | Phase 1/2 |